Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bryan Brewer

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
European Heart Journal|November 19, 2015
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysisMichael J Lipinski, Umberto Benedetto, Ricardo O Escarcega, et al.
Circulation|September 11, 2013
Translation of high-density lipoprotein function into clinical practice: current prospects and future challengesRobert S Rosenson, H Bryan Brewer, Benjamin Ansell, et al.
The Journal of Biological Chemistry|August 12, 2004
The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic miceHerminia González-Navarro, Zengxuan Nong, Marcelo J A Amar, et al.
Journal of Interventional Cardiology|February 13, 2014
Intravascular ultrasound analysis to determine the relationship between high-density lipoprotein cholesterol and lesion characteristics in patients with coronary artery diseaseHironori Kitabata, Joshua P Loh, Lakshmana K Pendyala, et al.
JAMA|November 18, 2011
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trialStephen J Nicholls, H Bryan Brewer, John J P Kastelein, et al.
Journal of Clinical Lipidology|May 22, 2016
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patientsStephen J Nicholls, Giacomo Ruotolo, H Bryan Brewer, et al.
Nature Reviews. Cardiology|September 2, 2015
Dysfunctional HDL and atherosclerotic cardiovascular diseaseRobert S Rosenson, H Bryan Brewer, Benjamin J Ansell, et al.
Journal of the American College of Cardiology|November 14, 2015
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With EvacetrapibStephen J Nicholls, Giacomo Ruotolo, H Bryan Brewer, et al.
Journal of the American College of Cardiology|December 18, 2020
Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial HypercholesterolemiaBrian B Ghoshhajra, Borek Foldyna, Daniel Gaudet, et al.
Lancet (London, England)|June 7, 2015
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trialG Kees Hovingh, John J P Kastelein, Sander J H van Deventer, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
European Heart Journal|November 19, 2015
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysisMichael J Lipinski, Umberto Benedetto, Ricardo O Escarcega, et al.
Circulation|September 11, 2013
Translation of high-density lipoprotein function into clinical practice: current prospects and future challengesRobert S Rosenson, H Bryan Brewer, Benjamin Ansell, et al.
The Journal of Biological Chemistry|August 12, 2004
The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic miceHerminia González-Navarro, Zengxuan Nong, Marcelo J A Amar, et al.
Journal of Interventional Cardiology|February 13, 2014
Intravascular ultrasound analysis to determine the relationship between high-density lipoprotein cholesterol and lesion characteristics in patients with coronary artery diseaseHironori Kitabata, Joshua P Loh, Lakshmana K Pendyala, et al.
JAMA|November 18, 2011
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trialStephen J Nicholls, H Bryan Brewer, John J P Kastelein, et al.
Journal of Clinical Lipidology|May 22, 2016
Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patientsStephen J Nicholls, Giacomo Ruotolo, H Bryan Brewer, et al.
Nature Reviews. Cardiology|September 2, 2015
Dysfunctional HDL and atherosclerotic cardiovascular diseaseRobert S Rosenson, H Bryan Brewer, Benjamin J Ansell, et al.
Journal of the American College of Cardiology|November 14, 2015
Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With EvacetrapibStephen J Nicholls, Giacomo Ruotolo, H Bryan Brewer, et al.
Journal of the American College of Cardiology|December 18, 2020
Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preβ-HDL-Enriched Plasma in Homozygous Familial HypercholesterolemiaBrian B Ghoshhajra, Borek Foldyna, Daniel Gaudet, et al.
Lancet (London, England)|June 7, 2015
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trialG Kees Hovingh, John J P Kastelein, Sander J H van Deventer, et al.
Pageof 8